We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
+4.46%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$6.63B
AUM Growth
+$3.92M
Cap. Flow
+$439M
Cap. Flow %
6.62%
Top 10 Hldgs %
41.1%
Holding
130
New
17
Increased
26
Reduced
9
Closed
10

Top Buys

Rank Stock Value
1
TMO icon
Thermo Fisher Scientific
TMO
+$228M
2
PEN icon
Penumbra
PEN
+$104M
3
TNYA icon
Tenaya Therapeutics
TNYA
+$52.8M
4
SGHT icon
Sight Sciences
SGHT
+$42.2M
5
MGNX icon
MacroGenics
MGNX
+$34.4M

Top Sells

Rank Stock Value
1
QDEL icon
QuidelOrtho
QDEL
+$113M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$74.8M
3
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$54.3M
4
MDXG icon
MiMedx Group
MDXG
+$27.1M
5
TRIL
Trillium Therapeutics Inc.
TRIL
+$20.3M

Sector Composition

Rank Sector Weight
1 Healthcare 91.48%
2 Financials 0.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IDYA icon
26
IDEAYA Biosciences
IDYA
$3.56B
$83.3M 1.26%
3,266,255
– –
MGNX icon
27
MacroGenics
MGNX
$257M
$83.2M 1.26%
3,975,554
+1,428,629
+56% +$34.4M
RXDX
28
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$77.4M 1.17%
3,264,031
– –
RGNX icon
29
Regenxbio
RGNX
$708M
$77.4M 1.17%
1,845,366
+87,623
+5% +$3.15M
CYTK icon
30
Cytokinetics
CYTK
$10.4B
$71.5M 1.08%
2,000,000
– –
ITOS
31
DELISTED
iTeos Therapeutics
ITOS
$63.5M 0.96%
2,353,015
+636,430
+37% +$16.6M
LABP
32
DELISTED
Landos Biopharma, Inc. Common Stock
LABP
$62.4M 0.94%
427,572
– –
CUTR
33
DELISTED
Cutera, Inc.
CUTR
$58.6M 0.88%
1,257,862
+537,045
+75% +$26.5M
AVDL
34
DELISTED
Avadel Pharmaceuticals
AVDL
$56.3M 0.85%
5,741,939
– –
PRQR icon
35
ProQR Therapeutics
PRQR
$265M
$53.9M 0.81%
6,443,113
– –
AXSM icon
36
Axsome Therapeutics
AXSM
$10.9B
$53.3M 0.8%
1,616,497
– –
TNYA icon
37
Tenaya Therapeutics
TNYA
$163M
$48.6M 0.73%
+2,458,750
New +$52.8M
AGEN
38
Agenus
AGEN
$290M
$47.6M 0.72%
462,343
-120,384
-21% -$13.6M
APYX icon
39
Apyx Medical
APYX
$171M
$47.1M 0.71%
3,398,279
+7,000
+0.2% +$73.6K
IMCR icon
40
Immunocore
IMCR
$1.73B
$46.2M 0.7%
1,245,532
– –
GHRS icon
41
GH Research
GHRS
$2.08B
$45.7M 0.69%
2,168,957
– –
OM icon
42
Outset Medical
OM
$90.8M
$44.2M 0.67%
59,643
+10,500
+21% +$7.15M
TARS icon
43
Tarsus Pharmaceuticals
TARS
$2.84B
$43.4M 0.65%
2,013,601
– –
ARGX icon
44
argenx
ARGX
$54.1B
$42.4M 0.64%
140,311
+108,559
+342% +$34.4M
LUNG icon
45
Pulmonx
LUNG
$87.6M
$41.9M 0.63%
1,164,600
+35,000
+3% +$1.38M
RLMD icon
46
Relmada Therapeutics
RLMD
$519M
$40.3M 0.61%
1,538,026
– –
CSTL icon
47
Castle Biosciences
CSTL
$979M
$39.8M 0.6%
599,009
-200,000
-25% -$14.1M
NSTG
48
DELISTED
NanoString Technologies, Inc.
NSTG
$38.6M 0.58%
804,029
– –
OLK
49
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
$32M 0.48%
1,318,188
+70,000
+6% +$2.2M
PTGX icon
50
Protagonist Therapeutics
PTGX
$9.44B
$31.1M 0.47%
1,753,695
-1,753,695
-50% -$74.8M
1
2
3 4 5

Similar funds

HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return

RTW Investments's Q3 2021 Portfolio in Review

As of Q3 2021, RTW Investments held 130 positions worth $6.63B, up 0.06% from $6.63B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

RTW Investments deployed $439M of net new capital in Q3 2021, opening 17 new positions and adding to 26 existing holdings. Its largest new stake was Thermo Fisher Scientific: 416,000 shares worth $238M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 88% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Protagonist Therapeutics, an estimated $74.8M trimmed.

  • RTW Investments's largest Q3 2021 buy was Thermo Fisher Scientific: 416,000 shares worth $238M.
  • RTW Investments added most to MacroGenics in Q3 2021, an estimated $34.4M increase.
  • RTW Investments's biggest Q3 2021 reduction was Protagonist Therapeutics, cutting an estimated $74.8M.
  • RTW Investments fully exited QuidelOrtho in Q3 2021, selling an estimated $113M.
  • RTW Investments's ten largest holdings make up 41% of its $6.63B portfolio in Q3 2021.
  • RTW Investments opened 17 new positions and closed 10 in Q3 2021.
  • RTW Investments's portfolio value rose 0.06% quarter-over-quarter to $6.63B.

Based on RTW Investments's 13F filing for Q3 2021, filed 15 Nov 2021.